These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 25282334

  • 1. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
    Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, Kumar S.
    Leuk Res; 2014 Nov; 38(11):1358-66. PubMed ID: 25282334
    [Abstract] [Full Text] [Related]

  • 2. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y, Liu W, Zhang L, Jia G.
    Med Sci Monit; 2017 Oct 29; 23():5150-5157. PubMed ID: 29080899
    [Abstract] [Full Text] [Related]

  • 3. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
    Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE, Zhang J, Ji Y, Younes A.
    Blood; 2012 Apr 26; 119(17):4017-25. PubMed ID: 22408261
    [Abstract] [Full Text] [Related]

  • 4. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L, Ma YP, Jia G.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov 26; 33(11):926-31. PubMed ID: 23363750
    [Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR.
    Leuk Res; 2011 Mar 26; 35(3):373-9. PubMed ID: 20650529
    [Abstract] [Full Text] [Related]

  • 6. [Effect of RAD001 or plus LBH589 on the proliferation, apoptosis and drug resistance in chemoresistant acute myeloid leukemic cells].
    Jiang XJ, Meng FY, Huang KK, Zhou HS, Wang Q.
    Zhonghua Yi Xue Za Zhi; 2011 Aug 30; 91(32):2287-92. PubMed ID: 22094098
    [Abstract] [Full Text] [Related]

  • 7. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
    Zhang L, Ma YP, Jia G, Lu YJ, Zhang L, Lu H, Chang MX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct 30; 20(5):1122-6. PubMed ID: 23114131
    [Abstract] [Full Text] [Related]

  • 8. Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors.
    Pietschmann K, Bolck HA, Buchwald M, Spielberg S, Polzer H, Spiekermann K, Bug G, Heinzel T, Böhmer FD, Krämer OH.
    Mol Cancer Ther; 2012 Nov 30; 11(11):2373-83. PubMed ID: 22942377
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC.
    Blood; 2006 Nov 15; 108(10):3441-9. PubMed ID: 16728695
    [Abstract] [Full Text] [Related]

  • 13. The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
    Klein JM, Henke A, Sauer M, Bessler M, Reiners KS, Engert A, Hansen HP, von Strandmann EP.
    PLoS One; 2013 Nov 15; 8(11):e79502. PubMed ID: 24278143
    [Abstract] [Full Text] [Related]

  • 14. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF.
    Cancer Res; 2006 Jun 01; 66(11):5781-9. PubMed ID: 16740717
    [Abstract] [Full Text] [Related]

  • 15. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, Sun KH, Sun GH, Chang SY, Yu DS, Hsiao PW, Huang SM, Cha TL.
    PLoS One; 2013 Jun 01; 8(9):e73401. PubMed ID: 24023871
    [Abstract] [Full Text] [Related]

  • 16. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F, Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, Wen-Li Z, Pei-Fang X, He Z, Guang-Hao S, Yan-Hong L, Yi-Ping L, Yun-Yun X, Hui-Ting Z, Yi W, Mei-Fang J, Lin L, Jian N, Shao-Yan H, Xue-Ming Z, Xing F, Jian W, Jian P.
    PLoS One; 2015 Jun 01; 10(7):e0126566. PubMed ID: 26176219
    [Abstract] [Full Text] [Related]

  • 17. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
    Bodo J, Zhao X, Sharma A, Hill BT, Portell CA, Lannutti BJ, Almasan A, Hsi ED.
    Br J Haematol; 2013 Oct 01; 163(1):72-80. PubMed ID: 23889282
    [Abstract] [Full Text] [Related]

  • 18. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
    Chao H, Wang L, Hao J, Ni J, Chang L, Graham PH, Kearsley JH, Li Y.
    Cancer Lett; 2013 Feb 01; 329(1):17-26. PubMed ID: 22995071
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
    Ye P, Zhao L, McGirr C, Gonda TJ.
    Cancer Lett; 2014 Feb 01; 343(1):98-106. PubMed ID: 24075958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.